Pharmaceutical Technology

MAY 10, 2023

Gilead Sciences has emerged victorious in a legal battle with the US government over patents surrounding the HIV pre-exposure prophylaxis (PrEP) drugs Descovy and Truvada following a federal jury’s verdict on May 9. The same jury also determined that these patents themselves are invalid, based on a May 9 Gilead statement.

Government 105

Government FDA Pharmaceutical Pharma 105

MedCity News

OCTOBER 13, 2022

Gilead Sciences is a leader in the field of virology treatments. As VP of clinical research for hepatitis, respiratory and emerging viruses at Gilead, Anu Osinusi talked about the pharma company’s work in HIV and hepatitis and how her personal background informed her team’s work in developing a Covid-19 treatment.

Pharma 104

Pharma Biopharma 104

MedCity News

OCTOBER 17, 2022

Gilead Sciences is betting that a MacroGenics antibody drug for blood cancers can offer a safety edge over others that address the same target. It’s the second partnership between the two companies; an alliance that began in 2013 expired without Gilead licensing any molecules from the deal.

Safety 78

Safety Biopharma Pharma 78

Pharmaceutical Technology

MAY 10, 2023

Gilead Sciences has acquired biotech company XinThera in an effort to bolster its oncology and inflammation pipeline. Gilead Sciences stated that the two programmes have the potential to address a number of indications and to provide development opportunities both alone and along with its wider portfolio.

Medicine 52

Medicine Marketing 52

European Pharmaceutical Review

OCTOBER 21, 2022

According to a new exclusive option and collaboration agreement between Gilead Sciences, Inc. and MacroGenics, Gilead will use MacroGenics’ DART® platform to develop MGD024, a potential therapy for blood cancers. Under the deal, Gilead will pay MacroGenics an initial $60 million. MacroGenics will be entitled up to $1.7

Pharmaceutical 85

Pharmaceutical Patients 85

European Pharmaceutical Review

AUGUST 10, 2022

Gilead Sciences has signed a definitive agreement to acquire outstanding share capital of clinical-stage biotechnology company MiroBio for around $405 million. Gilead said it anticipates advancing additional agonists derived from the I-ReSToRE platform over the “next several years.”

Networking 84

Networking Leads Pharmaceutical Patients 84

Pharmaceutical Technology

AUGUST 23, 2022

Gilead Sciences has obtained the European Commission (EC) marketing authorisation for Sunlenca (lenacapavir) injection and tablets to treat human immunodeficiency virus (HIV) infection. Earlier this month, the company entered a definitive agreement to acquire MiroBio for nearly $405m.

Food and Drug Administration 119

Food and Drug Administration Food Marketing Medicine 119

European Pharmaceutical Review

JULY 12, 2022

According to a recent survey of patient groups, Roche, Pfizer, ViiV Healthcare and Gilead Sciences are among the top companies for implementing and reporting progress on environmental, social, governance (ESG) activities.

Patients 96

Patients Ethics Government Pharma 96

European Pharmaceutical Review

JANUARY 4, 2023

EVOQ Therapeutics Inc has agreed to license its NanoDisc technology for rheumatoid arthritis (RA) and lupus to Gilead Sciences, Inc, enabling EVOQ to potentially receive up $658.5 The companies will collaborate to advance preclinical development and Gilead will be responsible for clinical development and commercialisation.

Sales 93

Sales Pharmaceutical 93

Pharmaceutical Technology

JULY 25, 2023

Gilead Sciences and IT company Cognizant have announced an expansion of their collaboration to expedite digital transformation.

52

52

pharmaphorum

AUGUST 3, 2022

Gilead Sciences’ investment in oncology has started to provide a solid return, with sales of cancer therapies breaching the $500 million threshold for the first time in the second quarter. Gilead acquired the drug as part of its $21 billion takeover of Immunomedics in 2020. billion, offsetting declines for older therapies.

Sales 95

Sales Management Marketing 95

MedCity News

AUGUST 15, 2022

Gilead Sciences said it has statistically significant and clinically meaningful data from a pivotal test of its cancer drug, Trodelvy, in the most common type of breast cancer.

FDA 81

FDA Patients Biopharma Pharma 81

Pharmaceutical Technology

MARCH 21, 2023

Gilead Sciences has exercised its option to exclusively license the investigational targeted protein degrader development candidate, NX‑0479, from clinical-stage biopharmaceutical company Nurix Therapeutics. GS-6791 is the first development candidate from the previous collaboration between Gilead Sciences and Nurix in 2019.

Sales 52

Sales Patients 52

Pharmaceutical Technology

JANUARY 4, 2023

Gilead Sciences has entered a collaboration and licensing agreement with EVOQ Therapeutics to advance the latter’s technology and develop immunotherapies to treat rheumatoid arthritis (RA) and lupus. Under the deal terms, the two companies will work together to advance the preclinical development of RA and lupus immunotherapies.

Medicine 52

Medicine Sales Pharmaceutical Patients 52

Pharmaceutical Technology

DECEMBER 28, 2022

Gilead Sciences and Jounce Therapeutics have amended their current license agreement for first-in-class immunotherapy, GS-1811 (formerly JTX-1811). The amended agreement will allow Gilead Sciences to acquire all the remaining rights for GS-1811 from Jounce Therapeutics. The initial license agreement was signed in 2020.

Medicine 52

Medicine Pharmaceutical Patients 52

Pharmaceutical Technology

MAY 5, 2023

The European Medicines Agency’s (EMA) committee for medicinal products for human use (CHMP) has recommended full marketing authorisation (MA) for Gilead Sciences ’ Hepcludex (bulevirtide) to treat chronic hepatitis delta virus (HDV) and compensated liver disease in adult patients.

Food and Drug Administration 59

Food and Drug Administration Marketing Medicine Food 59

Pharmaceutical Technology

AUGUST 5, 2022

Gilead Sciences has signed a definitive agreement for the acquisition of the complete outstanding share capital of MiroBio in a deal valued at nearly $405m in cash, subject to necessary adjustments. Prior to this development, the company reported a 1% revenue rise to $6.3bn in Q2 2022.

Networking 52

Networking Leads Pharmaceutical Patients 52

World of DTC Marketing

APRIL 7, 2021

Pfizer CEO Bourla’s Pay Climbed 17% to $21 Million in 2020 and Gilead Sciences CEO Daniel O’Day earned a $19 million take home. Pharma, PBM, and health insurance CEOs earn hundreds of millions of dollars to do one thing; make their companies a lot of money. Gilead Sciences, Daniel O’Day — $29.1

Healthcare 162

Healthcare Healthcare Food and Drug Administration Pharma 162

pharmaphorum

AUGUST 5, 2022

Less than three years after being spun out of Oxford University, privately-held biotech MiroBio is heading for a takeover by Gilead Sciences in a $405 million deal. The post Gilead snaps up MiroBio and its checkpoint agonists for $405m appeared first on.

Medicine 88

Medicine Sales Leads Patients 88

Pharmaceutical Technology

AUGUST 3, 2022

Gilead Sciences has reported a 1% growth in revenue to $6.3bn in the second quarter (Q2) of 2022 as against $6.2bn in the year-ago quarter. The company attributed the revenue rise to enhanced sales in HIV and oncology products, which was offset partially by reduced sales of Veklury (remdesivir) and hepatitis C virus (HCV) medicines.

Sales 52

Sales Medicine Pharmaceutical 52

European Pharmaceutical Review

JANUARY 4, 2023

EVOQ Therapeutics Inc has agreed to license its NanoDisc technology for rheumatoid arthritis (RA) and lupus to Gilead Sciences, Inc, enabling EVOQ to potentially receive up $658.5 The companies will collaborate to advance preclinical development and Gilead will be responsible for clinical development and commercialisation.

Sales 52

Sales Pharmaceutical 52

pharmaphorum

AUGUST 15, 2022

In the space of a couple of months, Gilead Sciences’ Trodelvy impact on overall survival (OS) in the TROPICs-02 trial in advanced breast cancer has gone from a trend to a statistically significant improvement, raising its chances of approval in a new indication.

Prospecting 66

Prospecting Sales Medical Patients 66

Pharmaceutical Technology

NOVEMBER 3, 2022

The US Food and Drug Administration (FDA) has granted approval for the supplemental new drug application (sNDA) of Gilead Sciences ’ Vemlidy (tenofovir alafenamide) to treat chronic hepatitis B virus (HBV) infection in paediatric patients.

Food and Drug Administration 52

Food and Drug Administration FDA Physicians Food 52

Pharmaceutical Technology

MAY 15, 2023

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies.

Pharmaceutical 64

Pharmaceutical Leads Pharma Medicine 64

World of DTC Marketing

OCTOBER 6, 2021

In the first 29 days of the trial, no deaths were reported among the 385 patients who received the drug, while eight of the people who received a placebo died, according to the statement put out by Merck and Ridgeback Biotherapeutics, the two companies that are jointly launching it. Gilead Sciences, Inc. The Intercept.

Food and Drug Administration 198

Food and Drug Administration Government Medicine Food 198

PM360

OCTOBER 3, 2023

Established in 2009, the Trailblazer Awards recognize and honor outstanding companies, marketers, marketing teams, brand managers, and initiatives that have demonstrated innovation and achieved incredible results in the life sciences.

Education 122

Education Marketing Media Management 122

Pharmaceutical Technology

DECEMBER 23, 2022

The US Food and Drug Administration (FDA) has granted approval for Gilead Sciences ’ Sunlenca (lenacapavir) plus other antiretroviral(s) (ARV) to treat human immunodeficiency virus type 1 (HIV-1) infection. The post FDA grants approval for Gilead’s multi-drug resistant HIV-1 treatment appeared first on Pharmaceutical Technology.

Food and Drug Administration 59

Food and Drug Administration FDA Food Medicine 59

World of DTC Marketing

NOVEMBER 27, 2020

Science by press release. Press releases only include the details the company wants to share and are carefully crafted. Moderna’s top management has, collectively, sold more than $350 million in stock or investments in the company over the course of this year.

Pharma 208

Pharma Food Safety Management 208

pharmaphorum

AUGUST 16, 2022

On the same day as it reported encouraging new data for its cancer drug Trodelvy, Gilead Sciences has agreed a deal to buy rights to the drug in Asia held by Chinese drugmaker Everest Medicines. The post On heels of new data, Gilead pays $455m for Asian Trodelvy rights appeared first on.

Prospecting 52

Prospecting Medicine Marketing Pharma 52

European Pharmaceutical Review

JANUARY 15, 2023

Key to the company’s ambitions for global growth will be a new state-of-the-art vaccine research, development and manufacturing facility in the UK. This will help to create new jobs and build on the strength of the UK’s life sciences ecosystem. In January 2022, Gilead joined the ABPI.

Pharmaceutical 92

Pharmaceutical Manufacturing Medicine Government 92

pharmaphorum

JANUARY 4, 2023

The Japanese pharma and Gilead Sciences – which licensed US rights to Lexiscan to the Japanese company – won a temporary reprieve against the launch of the generic back in the autumn, winning a temporary stay on launch until 6 December. It is sold as Rapiscan in Europe by GE Healthcare.

Pharmacology 57

Pharmacology Pharma Marketing Competition 57

World of DTC Marketing

OCTOBER 5, 2021

drug pricing system is filled with confusing numbers , and many entities profit off the flow of drugs, but pharmaceutical companies retain a vast majority of the proceeds” Big pharma IS big business. and the rest of the world include: Gilead Sciences’ HIV medication Biktarvy, which had U.S. Washington Post.

Pharma 241

Pharma Insurance Sales Government 241

Pharma Marketing Network

JULY 13, 2023

When consumers see that a company is willing to think outside the box, it shows that they are innovative and care about their customers. If done incorrectly, it can backfire and damage a company’s reputation. If done incorrectly, it can backfire and damage a company’s reputation.

Marketing 98

Marketing Pharma Media Pharmaceutical 98

Pharmaceutical Technology

MARCH 14, 2023

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies.

Leads 52

Leads Pharmaceutical 52

Pharmaceutical Technology

MARCH 14, 2023

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies.

Leads 72

Leads Biopharma Pharmaceutical Manufacturing 72

pharmaphorum

SEPTEMBER 26, 2022

The patents in question – owned by Gilead Sciences, which licenses them to Astellas – cover polymorphic forms of the active ingredient in Lexiscan. ” Hospira isn’t the only generics company trying to bring a version of regadenoson to the US market.

Pharmacology 52

Pharmacology FDA Pharma Marketing 52

Pharmaceutical Technology

MAY 15, 2023

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies.

Leads 52

Leads Biopharma Pharmaceutical Pharma 52